The FDA will review an application to consider potential approval of Nubeqa plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer. The Food and Drug Administration (FDA) ...
Phase II ARACOG (AFT-47) head-to-head trial met its primary endpoint, with patients treated with NUBEQA® (darolutamide) showing a decline in maximally changed cognitive domain (MCCD) by 24 weeks, with ...
Nubeqa (darolutamide) is a prescription drug that’s used to treat certain types of prostate cancer in adults. Nubeqa comes as an oral tablet. Nubeqa contains the active ingredient darolutamide. (An ...
Nubeqa plus ADT improved HRQoL and delayed pain progression in mHSPC patients, outperforming placebo plus ADT. The FDA approved Nubeqa for mHSPC based on ARANOTE trial data, highlighting its clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results